Clinical trials: Adenocarcinoma of the Prostate
Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Prostate Cancer
RET-Targeted Molecular Imaging Probes in Prostate Cancer
The goal of this observational diagnostic imaging study is to evaluate the value of RET-targeted PET/CT molecular imaging in diagnosing neuroendocrine prostate cancer (NEPC) and in assessing disease activity, treatment response…
- Trial name
- NCT07886138
- Testing
- RET-targeted PET/CT molecular imaging, PSMA-targeted PET/CT imaging
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with intermediate or high risk prostate cancer before surgery.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT03368547
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of Prostate
HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.
Investigators compare in a randomized clinical trial the results and side effects of high-dose- and low-dose-rate brachytherapy as monotherapy in the treatment of early, organ confined prostate cancer patients.
- Trial name
- PROMOBRA (NCT02258087)
- Testing
- LDR Brachytherapy, HDR Brachytherapy
- Where
- Hungary
- Volunteers
- 50 people
- Sponsor
- National Institute of Oncology, Hungary
Prostate Cancer
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003391
- Testing
- monoclonal antibody muJ591
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Weill Medical College of Cornell University
Prostatic Neoplasm, Prostate Cancer
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
The main purpose of this study was to determine whether ADT started before or after sipuleucel-T led to a better immune system response.
- Conditions
- Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
- Trial name
- NCT01431391
- Testing
- sipuleucel-T, leuprolide acetate
- Where
- 14 sites in United States
- Volunteers
- 68 people
- Sponsor
- Dendreon
Prostatic Adenocarcinoma
Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid
The present randomized, open, multicentric Phase II trial, in parallel groups with two arms of treatment, compares the treatment A, moderate hypofractionated radiotherapy of 62Gy, to treatment B, stereotactic irradiation of 37.5…
- Trial name
- RPAH2 (NCT02361515)
- Testing
- Moderate hypofractionated radiotherapy, Stereotactic radiotherapy
- Where
- 7 sites in France
- Volunteers
- 96 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Image Guided Radiation Therapy For Prostate Cancer
During the 7 to 8 weeks of conformal radiotherapy for prostate carcinoma, the prostate has an intra-pelvic motion which is not detectable by the conventional portal imaging.
- Trial name
- NCT00433706
- Testing
- Control position by 3DOBI before the fraction, Standard imaging
- Where
- France
- Volunteers
- 470 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostatic Neoplasms
Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer
The purpose of this study is to conduct a Phase I clinical trial involving in situ RTVP-1 gene therapy for prostate cancer. We will conduct necessary safety evaluations on a new adenovirus that contains the human genes for…
- Trial name
- NCT00403221
- Testing
- RTVP-1 Gene
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Baylor College of Medicine
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer
- Trial name
- NCT04249947
- Testing
- P-PSMA-101 CAR-T cells, Rimiducid
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poseida Therapeutics, Inc.
Prostate Cancer
Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276549
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Vitamin D and soy extract may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment.
- Trial name
- NCT00499408
- Testing
- Vitamin D, soy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate
RATIONALE: Calcitriol and dexamethasone may slow the growth of prostate cancer cells. PURPOSE: This randomized phase II trial is studying how well giving calcitriol together with dexamethasone before radical prostatectomy works…
- Trial name
- NCT00084864
- Testing
- calcitriol, dexamethasone, clinical observation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roswell Park Cancer Institute
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this phase II, single-arm, open-label, three center study is to evaluate the efficacy, safety, and tolerability of sEphB4-HSA in patients with mCRPC (metastatic castration-resistant prostate cancer).
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT04033432
- Testing
- Recombinant EphB4-HSA Fusion Protein
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Prostate Cancer, Prostate Adenocarcinoma
Defining Recurrent Disease With Axumin™
This project seeks to use advanced imaging (specifically, positron emission tomography/computed tomography [PET/CT]) to detect, locate, and characterize recurrent disease in the setting of patients with prostate cancer.
- Trial name
- NCT03996993
- Testing
- Casodex, Axumin, Salvage Radiation, Axumin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cancer Center of Irvine
Prostate Cancer, Adenocarcinoma of the Prostate
BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes
This study will evaluate approximately 3 months of treatment with the drug olaparib in patients with prostate cancer. A capsule formulation of olaparib (tradename Lynparza™) is approved by the United States Food and Drug…
- Trial name
- 337 (NCT03432897)
- Testing
- Olaparib Pill, Prostatectomy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Brown University
Prostate Cancer, Prostate Adenocarcinoma
Whole Versus Partial Gland Boost During Prostate SBRT
The purpose of this randomized phase II trial is to compare dose escalation of the prostate versus the dominant intra-prostatic lesion in a reduced fraction radiation therapy regimen.
- Trial name
- NCT07574489
- Testing
- Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska
Prostate Cancer
Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have stage II or…
- Trial name
- NCT00005096
- Testing
- docetaxel
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00006365
- Testing
- brachytherapy, iodine I 125, radiation therapy
- Where
- 254 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Adenocarcinoma, Prostate Carcinoma
DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
This study explores the potential use of DNA markers in the detection of prostate cancer and patient perceptions of this screening approach and other current or future prostate cancer screening and diagnostic tests.
- Trial name
- NCT06347809
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Fear of Cancer Recurrence, Prostate Cancer
Fear of Cancer Recurrence in Genitourinary Cancer
To perform an analysis of independent predictors of fear of cancer recurrence in patients with malignant genitourinary diseases and their impact on quality of life and survival
- Conditions
- Fear of Cancer Recurrence, Prostate Cancer, Renal Cell Cancer, Urothelial Carcinoma
- Trial name
- NCT04535921
- Testing
- FCR7 questionnaire
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Ludwig-Maximilians - University of Munich